

## **Reliq Health Technologies, Inc. Announces Contracts with Five New Clients in the US**

HAMILTON, Ontario, Dec. 02, 2021 — **Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB)** (“**Reliq**” or the “**Company**”), a rapidly growing global medtech company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed contracts with five new US clients, including three physician practices, a home health agency and a hospice provider.

“We are pleased to be adding three primary care practices, a home health agency and a hospice care provider as new clients,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “As the Omicron variant raises new concerns about COVID transmission this winter, clinicians are even more motivated to keep their high-risk patients healthy and at home. Reliq’s iUGO Care platform helps protect chronic disease patients by allowing them to receive high quality healthcare in their own homes, avoiding the potential exposure to COVID and flu viruses in clinic and hospital settings. These five new contracts will add over 2,000 new Medicare patients to our platform in Q1 Calendar Year 2022 at an average revenue of over \$50 USD per patient per month. Onboarding will begin in the new year.”

### **Reliq Health**

Reliq Health Technologies is a rapidly growing global medtech company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.

ON BEHALF OF THE BOARD

“Dr. Lisa Crossley”

CEO and Director

**For further information please contact:**

### **Company Contact**

Investor Relations at [ir@reliqhealth.com](mailto:ir@reliqhealth.com)

### **US Investor Relations Contact**

Investor Relations

Lytham Partners, LLC  
Ben Shamsian  
New York | Phoenix  
646-829-9701  
[shamsian@lythampartners.com](mailto:shamsian@lythampartners.com)

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

### **Cautionary Statements Regarding Forward Looking Information**

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “**Company**”) does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.

